Stocks Health care MNPR
NASDAQ · Health careMonopar Therapeutics (MNPR)
It posted a net loss of $17.8M. At June 30, 2026 it held $52.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Monopar Therapeutics
- Net worth
- Monopar Therapeutics has a market value (market cap) of $481.8M at the latest share price, and shareholders' equity of $130.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $13.7M.
- Cash flow
- In fiscal 2025 operations used $12.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Monopar Therapeutics's next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Monopar Therapeutics does
Monopar Therapeutics is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MNPR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$13.7M | -$1.85 | n/a |
| 2024 | $0 | -$15.6M | -$4.11 | n/a |
| 2023 | n/a | -$8.4M | -$3.04 | n/a |
| 2022 | n/a | -$10.5M | -$4.14 | n/a |
| 2021 | n/a | -$9.1M | -$3.64 | n/a |
| 2020 | n/a | -$6.3M | -$2.89 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Monopar Therapeutics has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
- July 22, 2026Form S-8 POS filing S-8 POS
- July 22, 2026Form S-8 POS filing S-8 POS
- July 22, 2026Form S-8 POS filing S-8 POS
- July 22, 2026Form S-8 POS filing S-8 POS
- July 22, 2026
Insider trades
What the people running Monopar Therapeutics did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $5.3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Tsuchimoto Kim RDirector | Exercised options | 856 | $25.7K |
| November 4, 2026 | Tsuchimoto Kim RDirector | Exercised options | 2,035 | $28.5K |
| November 4, 2026 | Tsuchimoto Kim RDirector | Soldpre-planned (10b5-1) | 1,295 | $91.6K |
| November 4, 2026 | Tsuchimoto Kim RDirector | Soldpre-planned (10b5-1) | 996 | $71.1K |
| November 4, 2026 | Tsuchimoto Kim RDirector | Soldpre-planned (10b5-1) | 600 | $43.3K |
| November 2, 2026 | Tsuchimoto Kim RDirector | Exercised options | 1,199 | $36K |
| November 2, 2026 | Tsuchimoto Kim RDirector | Soldpre-planned (10b5-1) | 1,199 | $84K |
| November 2, 2026 | Anderson RaymondDirector | Exercised options | 1,402 | $42.1K |
Who owns MNPR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive with 1 related filers | 19.5% | November 14, 2025 |
| Chandler Robinson13D, may seek influence with 4 related filers | 19.2% | December 17, 2024 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | February 17, 2026 |
| BlackRock, Inc.13G, passive | 5.03% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 96 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 1,312,129 | new |
| RA Capital Management, L.P. | 667,207 | 0 |
| BlackRock, Inc. | 348,819 | +32,252 |
| Deerfield Management Company, L.P. | 323,745 | 0 |
| Saturn V Capital Management LP | 311,976 | -33,650 |
| Siren, L.L.C. | 270,118 | 0 |
| ADAR1 Capital Management, LLC | 217,595 | -46,683 |
| Polar Capital Holdings Plc | 214,469 | -12,057 |
| Vanguard Capital Management LLC | 209,711 | -8,752 |
| Adage Capital Partners GP, L.L.C. | 209,195 | -100,000 |
| TCG Crossover Management, LLC | 203,327 | +71,224 |
| Wellington Management Group Llp | 158,437 | -15,905 |
| Orbimed Advisors LLC | 157,423 | new |
| Candriam S.C.A. | 143,339 | new |
| Balyasny Asset Management L.P. | 134,543 | -1,900 |
| Geode Capital Management, LLC | 112,578 | +12,660 |
| Alyeska Investment Group, L.P. | 100,000 | 0 |
| State Street Corp | 92,551 | +4,196 |
| Vivo Capital, LLC | 90,500 | 0 |
| Driehaus Capital Management LLC | 84,040 | +50,884 |
Insiders
8 insiders reported holding 819,604 shares in total, about $58.8M at the last price.
| Holder | Shares |
|---|---|
| Hendricks Diane10% owner | 567,580567,580 held indirectly |
| Robinson ChandlerChief Executive Officer, Director | 166,94262,815 held indirectly |
| Cittadine AndrewChief Operating Officer | 58,054 |
| Klausner Arthur JDirector | 8,762 |
| Anderson RaymondDirector | 5,373 |
| Starr Christopher MDirector | 5,173 |
| Rioux PatriceActing Chief Medical Officer | 5,065 |
| Vu Quan AnhChief Financial Officer | 2,655 |
Questions about MNPR
What does Monopar Therapeutics do?
Monopar Therapeutics is a company in the Health care sector, listed on NASDAQ as MNPR. Its shares trade on NASDAQ under the ticker MNPR.
What is Monopar Therapeutics's net worth?
Monopar Therapeutics has a market value (market cap) of $481.8M at the latest share price, and shareholders' equity of $130.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Monopar Therapeutics profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $17.8M.
When did Monopar Therapeutics last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Monopar Therapeutics's next earnings report?
Monopar Therapeutics's next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MNPR with
Follow MNPR
Get an email when Monopar Therapeutics files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Monopar Therapeutics tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.